Spring Bank spears $10.5m Series A round for Phase I selective HCV drug
This article was originally published in Scrip
Executive Summary
Spring Bank Pharmaceuticals raised $10.5 million in a Series A funding round to take a new mechanism of action for the treatment of hepatitis C virus (HCV) into clinical development via its lead oral, small molecule drug candidate SB 9200.